Genetic Carrier Screening Before IVF: What Every Patient Should Test

You can be perfectly healthy and still carry a gene for a serious genetic disease. That's not unusual — most people carry at least one recessive mutation for conditions like cystic fibrosis, sickle cell disease, spinal muscular atrophy, or Tay-Sachs disease. You'll never know unless you test. And the time to test is before you start IVF, not after.

What Is Carrier Screening?

Carrier screening is a blood test (or saliva test) that checks whether you carry recessive genetic mutations. Being a "carrier" means you have one copy of a mutated gene but no symptoms — you need two copies (one from each parent) for the disease to manifest.

When both partners are carriers of the same condition, each pregnancy has a 25% chance of producing an affected child. That's the scenario carrier screening is designed to identify — before conception, not after.

Why ACOG Recommends It for Everyone

The American College of Obstetricians and Gynecologists (ACOG) updated its guidance to recommend that expanded carrier screening be offered to all patients planning pregnancy, regardless of ethnicity or family history. The previous approach — testing for specific conditions based on ethnic background (Tay-Sachs for Ashkenazi Jews, sickle cell for African Americans) — missed too many carriers in an increasingly diverse population.

Modern expanded carrier panels test for 200+ conditions from a single blood draw, including:

• Cystic fibrosis (1 in 25 Caucasians are carriers)
• Spinal muscular atrophy (1 in 40–50 across all ethnicities)
• Sickle cell disease and thalassemias
• Fragile X syndrome
• Tay-Sachs disease
• Phenylketonuria (PKU)
• Congenital adrenal hyperplasia
• Dozens of rarer metabolic, neurological, and developmental conditions

Cost Comparison

Some US insurance plans cover carrier screening; many don't, or cover only a limited panel. In Colombia, the full expanded panel is available at $500–$1,500 — a fraction of the US out-of-pocket cost.

What Happens If Both Partners Are Carriers

If both you and your partner carry mutations for the same condition, you have options — and this is where IVF becomes medically indicated rather than elective:

PGT-M (Preimplantation Genetic Testing for Monogenic Disorders)

PGT-M tests embryos for the specific genetic condition identified by carrier screening. Only unaffected embryos (those with zero or one copy of the mutation) are transferred. This is the most proactive approach — it prevents the condition before pregnancy begins.

PGT-M is a specialized form of genetic testing distinct from PGT-A (which screens for chromosomal abnormalities). It requires the development of a custom probe specific to your mutation, which takes 2–4 weeks and costs $2,000–$4,000 in Colombia (vs. $4,000–$8,000 in the US).

Other Options If Both Partners Are Carriers

Donor gametes: Using donor sperm or donor egg from a non-carrier eliminates the risk without PGT-M. Donor screening includes carrier testing for common conditions.

Prenatal diagnosis: CVS (chorionic villus sampling) at 10–12 weeks or amniocentesis at 15–20 weeks can test an existing pregnancy. However, this approach means deciding whether to continue a pregnancy with an affected fetus — a decision many families prefer to avoid by testing embryos before transfer.

Screening for Donor Gamete Recipients

If you're using donor sperm or donor egg, carrier screening is equally important — but the focus shifts to matching. The goal is to ensure that the donor and the patient providing the complementary gamete don't share carrier status for the same condition.

Reputable sperm and egg banks screen donors for common carrier conditions. Your fertility clinic can cross-reference donor carrier results with your own to identify any overlapping risks before proceeding.

When to Get Tested

Ideally, both partners should complete carrier screening before starting IVF. This timeline allows you to:

• Review results without time pressure
• Develop a PGT-M probe if needed (2–4 weeks)
• Make informed decisions about whether PGT-M, donor gametes, or proceeding without testing is right for your family
• Include carrier screening costs in your overall treatment budget

If you've already started IVF without carrier screening, it's not too late. Embryos can be frozen after biopsy while PGT-M probes are developed and testing is completed. The delay is weeks, not months.

Emotional Considerations

Learning that you carry a genetic mutation can be unsettling, even though carrier status is extremely common (most people carry 1–2 recessive mutations). It does not mean you are unhealthy or that something is "wrong" with you. It means you have valuable information that allows you to make informed reproductive decisions — which is exactly the point.

If both partners are carriers of the same condition, the conversation shifts from screening to decision-making: PGT-M, donor gametes, or accepting the 25% risk. These are deeply personal choices, and a genetic counselor can help you understand the specific condition, its severity, and your options.